24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Child & Adolescent Development: Overview
Resources
Basic InformationMore InformationLatest News
Health Tip: Identifying Chicken PoxCould Pests, Dust Lower Kids' Odds for Asthma?When a Cold or Flu Strikes a Family MemberBooze Often Glorified On YouTube VideosInflammatory Bowel Disease May Raise Cancer Risk in KidsKids' Colds Linked to Asthma, Lung Problems LaterAAP: Few Doctors Provide Firearm Injury Prevention Info in ERDoctors Eye the Danger From 'Nerf' GunsParents Say Schools Don't Help Kids With Mental Health, Chronic DiseaseIt's a Food Allergy! Where's the School Nurse?Big Rise in Hospitalized Kids With Opioid Side EffectsAAP: Opioid Dependence/Abuse Public Health Issue for ChildrenGolf Carts' Use Is Spreading, and So Is Danger to KidsState Laws Have Big Impact on Kids' Gun InjuriesHealth Tip: On Kids and Pets'Microbiomes' May Hold Key to Kids' Ear InfectionsHurricanes May Have Longer-Lasting Impact on KidsHeath Tip: Getting Rid of Head LiceState Laws Curb Kids' Injuries Tied to Off-Road VehiclesBrown-Bagging It? Think Outside the BoxVaccine Campaign in Poor Countries to Save 20 Million LivesGuinea Pigs Harbor a Hidden Health HazardFor City Kids With Asthma, Nearby Green Space Is KeyEarly Respiratory Infections Tied to Celiac in High-Risk ChildrenHealth Tip: Fuel Your Child With a Good BreakfastIncrease in Medical Exemptions From Immunization in CaliforniaPut Flu Shot on the Back-to-School ChecklistSmoking Bans Help Kids Breathe EasierThroat Bacteria Linked to Bone and Joint Infection in KidsHarvey's Wrath Still Poses Risks to ChildrenHeath Tip: It's Back-to-School TimeHelping Kids Adapt to a New SchoolWhite Kids More Likely to Get Unneeded AntibioticsBack to School, Back to Planning for Kids With Autism, ADHDTake the Back Pain Out of BackpacksChild Flu Vaccination Down When Nasal Spray UnavailableNasal Flu Vaccine's Demise May Mean Fewer Immunized KidsHealth Tip: Identify BullyingHealth Tip: Prepare for Your Child's Dental ProcedureIntracranial Pressure Monitoring No Benefit in Pediatric TBIFDA Approves 1st Treatment for 'Kissing Bug' Illness in ChildrenMany Parents Don't Tell Doctor About 'Complementary' Therapy Use in KidsHealth Tip: Back to School for Kids with AsthmaVaccination 101: Make Sure Kids Are Up to DateSerious Reactions to Vaccines Rarely Recur: ReviewParents Worried About Cyberbullies as School Starts UpCookies, Apples or Yogurt? Not Always a Simple Choice for KidsCyberbullying Weighs Heavily on Young PeopleHaving Same-Sex Parents Won't Affect Kids' Gender Identity: StudyKids' Cases of High Blood Pressure May Rise Under New Guidelines
Questions and AnswersLinks
Related Topics

ADHD: Attention Deficit Hyperactivity Disorder
Childhood Mental Disorders and Illnesses
Child Development & Parenting: Infants (0-2)
Child Development & Parenting: Early (3-7)

Direct-Acting Antivirals Approved for Children 12+ With HCV


HealthDay News
Updated: Apr 10th 2017

new article illustration

MONDAY, April 10, 2017 (HealthDay News) -- The U.S. Food and Drug Administration has approved two drugs to treat hepatitis C virus (HCV) infection in children aged 12 and older.

Sovaldi (sofosbuvir) and Harvoni (ledipasvir, sofosbuvir) are the first direct-acting antiviral treatments approved for children and adolescents with HCV, the agency said in a news release Friday.

The two approvals provide pediatric treatment options for six major genotypes of HCV: Harvoni is indicated for the treatment of pediatric patients ≥12 years or weighing ≥35 kg with HCV genotype 1, 4, 5, or 6 infection without cirrhosis or with mild cirrhosis. Sovaldi in combination with ribavirin is indicated for the treatment of pediatric patients ≥12 years or weighing ≥35 kg with HCV genotype 2 or 3 infection without cirrhosis or with mild cirrhosis.

In clinical studies, the most common side effects of both drugs were fatigue and headache. Health care professionals should screen all patients for evidence of current or prior hepatitis B virus infection before starting treatment with Harvoni or Sovaldi, the agency advised.

"These approvals will help change the landscape for HCV treatment by addressing an unmet need in children and adolescents," Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research, said in a statement.

Harvoni and Sovaldi are marketed by Gilead Sciences, in Foster City, Calif.

More Information